Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vanguard High Dividend Yield ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.14B), while Vanguard High Dividend Yield ETF trades at $158.5 (market cap $100.80B). The key difference: Vanguard High Dividend Yield ETF is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Vanguard High Dividend Yield ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Vanguard High Dividend Yield ETF for 138 Days on average.
| REGN | VYM | |
|---|---|---|
Market Cap | $76.14B | $100.80B |
Volume | 500,239 | 993,696 |
Sector | Health | — |
52-Week High | $852.03 | $167.03 |
52-Week Low | $557.73 | $137.47 |
Typical Hold Time | 107 Days | 138 Days |
Enterprise Value | $70.85B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
VYM trades at $157.45, down 0.58% on the day, with a bearish technical signal from moving averages while oscillators remain neutral. The ETF's 2.42% yield provides consistent income, though recent articles highlight performance comparisons with peers like SCHD and IDV. Support and resistance levels cluster tightly around $157-158, indicating potential for near-term price consolidation.
The outlook remains cautious as VYM faces competitive pressure from higher-yielding alternatives and concerns about dividend sustainability in its holdings. While diversification and low costs are strengths, investors should weigh the trade-offs between yield consistency and total return potential in the current market environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
